Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mocravimod
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Priothera
Deal Size : Undisclosed
Deal Type : Collaboration
EUROAPI and Priothera enter into CDMO collaboration to advance oncology project
Details : The collaboration aims to support Protheria for the development and manufacturing KRP203 (mocravimod), which is being evaluated in the late-stage for the treatment of adult acute myeloid leukemia.
Brand Name : KRP203
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 18, 2024
Lead Product(s) : Mocravimod
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Priothera
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
CDMO: EUROAPI Supports Sanofi’s mRNA Vaccine Platform with The Development of Lipid Nanoparticles
Details : EUROAPI will focus on lipids that are currently being tested as part of Phase I/II clinical trials that will support Sanofi’s mRNA vaccines platform, targeting indications including Flu.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
May 30, 2022
Lead Product(s) : mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
KEY PRODUCTS
Reset All
EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.